|   |   | 
Legal status
Patent not validated
| (51) | INT.CL. | C12Q 1/6886 | |
| G01N 33/574 | |||
| C12N 9/12 | |||
| A61P 35/00 | |||
| A61P 35/02 | |||
| A61P 35/04 | 
| (11) | Number of the document | 3333259 | 
| (13) | Kind of document | T | 
| (96) | European patent application number | 17201390.6 | 
| Date of filing the European patent application | 2011-06-09 | |
| (97) | Date of publication of the European application | 2018-06-13 | 
| (45) | Date of publication and mention of the grant of the patent | 2021-02-24 | 
| (46) | Date of publication of the claims translation | 
| (30) | Number | Date | Country code | 
| 352959 P | 2010-06-09 | US | 
| (72) | 
                    
                    
                    
                    
                    GARRAWAY, Levi, A., US  
                    
                    
                    
                    
                    EMERY, Caroline, US  
                    
                    
                    
                    
                    WAGLE, Nikhil, US  | 
| (73) | Dana Farber Cancer Institute, Inc.,
                450 Brookline Avenue, Boston, Massachusetts 02215,
                US | 
| (54) | A MEK1 MUTATION CONFERRING RESISTANCE TO RAF AND MEK INHIBITORS | 
| A MEK1 MUTATION CONFERRING RESISTANCE TO RAF AND MEK INHIBITORS |